Binocrit

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

epoetin alfa

Available from:

Sandoz GmbH

ATC code:

B03XA01

INN (International Name):

epoetin alfa

Therapeutic group:

Antianemijski pripravci

Therapeutic area:

Anemia; Kidney Failure, Chronic

Therapeutic indications:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. stanje kardiovaskularnog sustava, već postojeće anemije u početku kemoterapije).

Product summary:

Revision: 22

Authorization status:

odobren

Authorization date:

2007-08-28

Patient Information leaflet

                                74
B. UPUTA O LIJEKU
75
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
BINOCRIT 1000 IU/0,5 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 2000 IU/1 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 3000 IU/0,3 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 4000 IU/0,4 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 5000 IU/0,5 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 6000 IU/0,6 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 7000 IU/0,7 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 8000 IU/0,8 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 9000 IU/0,9 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 10 000 IU/1 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 20 000 IU/0,5 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
BINOCRIT 30 000 IU/0,75 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ
ŠTRCALJKI
BINOCRIT 40 000 IU/1 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
epoetin alfa
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Binocrit i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati Binocrit
3.
Kako primjenjivati Binocrit
4.
Moguće nuspojave
5.
Kako čuvati Binocrit
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE BINOCRIT I ZA ŠTO SE KORISTI
Binocrit sadrži djelatnu tvar epoetin alfa, protein koji potiče
koštanu srž da proizvodi više crvenih
krvnih stanica koje sadrže hemoglobin (tvar koja prenosi ki
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Binocrit 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 3000 IU/0,3 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 6000 IU/0,6 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 7000 IU/0,7 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Binocrit 30 000 IU/0,75 ml otopina za injekciju u napunjenoj
štrcaljki
Binocrit 40 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Binocrit 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Jedan ml otopine sadrži 2000 IU epoetina alfa
*
, što odgovara 16,8 mikrograma po ml. Napunjena
štrcaljka od 0,5 ml sadrži 1000 međunarodnih jedinica (IU), što
odgovara 8,4 mikrograma epoetina
alfa. *
Binocrit 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
Jedan ml otopine sadrži 2000 IU epoetina alfa
*
, što odgovara 16,8 mikrograma po ml. Napunjena
štrcaljka od 1 ml sadrži 2000 međunarodnih jedinica (IU), što
odgovara 16,8 mikrograma epoetina
alfa. *
Binocrit 3000 IU/0,3 ml otopina za injekciju u napunjenoj štrcaljki
Jedan ml otopine sadrži 10 000 IU epoetina alfa
*
, što odgovara 84,0 mikrograma po ml. Napunjena
štrcaljka od 0,3 ml sadrži 3000 međunarodnih jedinica (IU), što
odgovara 25,2 mikrograma epoetina
alfa. *
Binocrit 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki
Jedan ml otopine sadrži 10 000 IU epoetina alfa
*
, što odgovara 84,0 mikrograma po ml. Napunjena
štrcaljka od 0,4 ml sadrži 4000 međunarodnih je
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-11-2023
Public Assessment Report Public Assessment Report Bulgarian 04-10-2018
Patient Information leaflet Patient Information leaflet Spanish 21-11-2023
Public Assessment Report Public Assessment Report Spanish 04-10-2018
Patient Information leaflet Patient Information leaflet Czech 21-11-2023
Public Assessment Report Public Assessment Report Czech 04-10-2018
Patient Information leaflet Patient Information leaflet Danish 21-11-2023
Public Assessment Report Public Assessment Report Danish 04-10-2018
Patient Information leaflet Patient Information leaflet German 21-11-2023
Public Assessment Report Public Assessment Report German 04-10-2018
Patient Information leaflet Patient Information leaflet Estonian 21-11-2023
Public Assessment Report Public Assessment Report Estonian 04-10-2018
Patient Information leaflet Patient Information leaflet Greek 21-11-2023
Public Assessment Report Public Assessment Report Greek 04-10-2018
Patient Information leaflet Patient Information leaflet English 21-11-2023
Public Assessment Report Public Assessment Report English 04-10-2018
Patient Information leaflet Patient Information leaflet French 21-11-2023
Public Assessment Report Public Assessment Report French 04-10-2018
Patient Information leaflet Patient Information leaflet Italian 21-11-2023
Public Assessment Report Public Assessment Report Italian 04-10-2018
Patient Information leaflet Patient Information leaflet Latvian 21-11-2023
Public Assessment Report Public Assessment Report Latvian 04-10-2018
Patient Information leaflet Patient Information leaflet Lithuanian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-11-2023
Public Assessment Report Public Assessment Report Lithuanian 04-10-2018
Patient Information leaflet Patient Information leaflet Hungarian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 21-11-2023
Public Assessment Report Public Assessment Report Hungarian 04-10-2018
Patient Information leaflet Patient Information leaflet Maltese 21-11-2023
Public Assessment Report Public Assessment Report Maltese 04-10-2018
Patient Information leaflet Patient Information leaflet Dutch 21-11-2023
Public Assessment Report Public Assessment Report Dutch 04-10-2018
Patient Information leaflet Patient Information leaflet Polish 21-11-2023
Public Assessment Report Public Assessment Report Polish 04-10-2018
Patient Information leaflet Patient Information leaflet Portuguese 21-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 21-11-2023
Public Assessment Report Public Assessment Report Portuguese 04-10-2018
Patient Information leaflet Patient Information leaflet Romanian 21-11-2023
Public Assessment Report Public Assessment Report Romanian 04-10-2018
Patient Information leaflet Patient Information leaflet Slovak 21-11-2023
Public Assessment Report Public Assessment Report Slovak 04-10-2018
Patient Information leaflet Patient Information leaflet Slovenian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 21-11-2023
Public Assessment Report Public Assessment Report Slovenian 04-10-2018
Patient Information leaflet Patient Information leaflet Finnish 21-11-2023
Public Assessment Report Public Assessment Report Finnish 04-10-2018
Patient Information leaflet Patient Information leaflet Swedish 21-11-2023
Public Assessment Report Public Assessment Report Swedish 04-10-2018
Patient Information leaflet Patient Information leaflet Norwegian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 21-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 21-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 21-11-2023

Search alerts related to this product

View documents history